Early access
Sign in
Active, not recruitingNo phase

Real-world Study on Fenestrated Stent for Thoracic Aortic Dissection

Key facts

Who runs it
Qingyou Meng
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
320 people enrolled
Started
1 Dec 2024
Expected to end
30 Nov 2027
Type of study
Observational
Treatments tested
  • TALOS
Record updated
8 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients scheduled for or already receiving the Talos stent
  • Age ≥18 years, any gender, non-pregnant or non-lactating
  • Diagnosed with aortic dissection
  • Presence of a ≥15mm effective proximal landing zone
  • Having eligible access artery anatomy
  • Expected survival >1 year
  • Capable of understanding the trial purpose, voluntarily participating, signing informed consent, and willing to undergo follow-up

Who cannot take part

  • Concurrent participation in other drug/device trials without completing primary endpoints
  • Other investigator-determined contraindications for endovascular therapy (e.g., unsuitable vascular access, non-cooperation)
  • Definitive diagnosis of aortic-related connective tissue disorders (e.g., Marfan syndrome)
  • Documented allergy to nitinol alloys, contrast agents, or related materials
  • Uncontrolled severe infections (e.g., bacteremia or septicemia)
  • History of active bleeding, coagulopathy, or refusal of blood transfusion
  • Malignancy with life expectancy <1 year
  • Severe hepatic/renal dysfunction (ALT or AST >2.5×ULN, serum creatinine >2×ULN)
  • Subjects with infectious aortic dissection
  • Pregnancy, lactation, or planned pregnancy during the trial
  • Poor compliance with anticipated inability to complete follow-up

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Study Title:

Read full original descriptionShow less

"Multi-center Real-world Study on Straight Tubular Thoracic Aortic Perforated Stent-Graft System for Treating Thoracic Aortic Dissection"

Purpose:

This study aims to evaluate the effectiveness of the Talos stent-graft system, a new device designed to treat aortic dissection (a life-threatening condition where the inner layer of the aorta tears). The stent has unique features like perforations and tapered design to reduce complications compared to traditional stents.

Key Features of the Talos Stent:

Longer length to cover more of the damaged aorta Perforated design at the distal end to improve blood flow Tapered shape to better match natural aortic anatomy Potentially reduces risks like new tears or spinal cord ischemia

Study Details:

Type: Real-world study (combining prospective and retrospective data) Duration: 3 years (2024-2027) Participants: 320 patients across 5 major hospitals in Shanghai Follow-up: Regular check-ups at 1, 3, 6, 12, and 24 months post-surgery Who Can Participate?

Patients may qualify if they:

Are ≥18 years old Have aortic dissection requiring treatment Have suitable blood vessels for stent placement Can commit to follow-up visits Who Cannot Participate?

Patients with:

Connective tissue disorders (e.g., Marfan syndrome) Active infections or cancer with limited life expectancy Severe allergies to stent materials/contrast dye Pregnancy or planning pregnancy What Does Participation Involve? Pre-Surgery: Physical exams, blood tests, CT scans Surgery: Minimally invasive stent placement via groin artery Post-Surgery: Blood pressure management, antiplatelet medication (e.g., aspirin) Follow-up: CT scans and quality-of-life questionnaires

Potential Benefits:

Improved aortic healing Reduced need for repeat surgeries Better quality of life (measured by VascuQoL questionnaire)

Possible Risks:

Standard stent risks (bleeding, infection, allergic reactions) Device-related complications (leaks, migration, new tears) Organ ischemia (reduced blood flow to kidneys/other organs)

Safety Monitoring:

Independent review of all CT scans 24/7 access to vascular specialists Immediate reporting of any complications

Ethical Protections:

Approved by ethics committees at all hospitals Voluntary participation with signed consent Right to withdraw anytime without affecting care

For Healthcare Providers:

This investigator-initiated study (IIS) is funded by Shanghai Science \& Technology Commission. It uses standardized protocols across centers with electronic data capture (EDC) for consistency. The primary endpoint is 12-month treatment success (defined as technical success + no reintervention). Secondary endpoints include aortic remodeling rates and complication profiles.

Contact Information:

Principal Investigator: Dr. Meng Qingyou Institution: Shanghai General Hospital Phone: +86-133-0621-1019

The group in the trial

  • TALOS USED GROUP

    Population who have received TALOS stents

    Treatment: TALOS

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multi-center, Real-world Study on the Treatment of Thoracic Aortic Dissection With a Straight-type Fenestrated Covered Stent System for Thoracic Aortic Aneurysms
Record updated
8 December 2025